Gastrointestinal symptoms in acromegaly: A case control study

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 11, Issue 2

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Journal Information of This Article

Publication Name

World Journal of Gastrointestinal Pharmacology and Therapeutics

ISSN

2150-5349

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Case Control Study

World J Gastrointest Pharmacol Ther. Jun 9, 2020; 11(2): 17-24
Published online Jun 9, 2020. doi: 10.4292/wjgpt.v11.i2.17

Table 1 Acromegaly demographic and treatment data

	Controls	Acromegaly patients
n	200	50
M:F	96:104	24:26
Age at diagnosis (mean, yr)	33	32.44
Years since diagnosis (mean, yr)	-	11.8 yr
Transsphenoidal surgery	-	50 (100%)
Pituitary radiotherapy	-	21 (42%)
Somatostatin analogue	-	37 (74%)

Citation: Inayet N, Hayat J, Bano G, Poullis A. Gastrointestinal symptoms in acromegaly: A case control study. World J Gastrointest Pharmacol Ther 2020; 11(2): 17-24
URL: https://www.wjgnet.com/2150-5349/full/v11/i2/17.htm
DOI: https://dx.doi.org/10.4292/wjgpt.v11.i2.17

Inayet N, Hayat J, Bano G, Poullis A. Gastrointestinal symptoms in acromegaly: A case control study. World J Gastrointest Pharmacol Ther 2020; 11(2): 17-24 [PMID: 32550042 DOI: 10.4292/wjgpt.v11.i2.17]

All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.